This phase I trial is trying to understand how safe a new cancer immunotherapy is for the treatment of patients with advanced cancer that have not responded to or are unable to receive other treatment.
This trial is treating patients with advanced solid cancer (in part 1), including kidney cancer and skin cancer (in part 2).
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A First-in-Human Phase 1 Study of NL-201 in Patients With Relapsed or Refractory Cancer
Neoleukin Therapeutics, Inc.
This is a dose escalation and expansion trial. Eligible patients will receive NHL-201 intravenously, testing ascending doses and two different schedules. Tumour response to treatment will be assessed every 6-weeks for 12 weeks, and every 12 weeks thereafter until disease progression. Patients enrolled in the expansion phase of this trial will receive NHL-201 intravenously at a dose and schedule determined in the escalation phase.
Recruiting Hospitals Read More